Fund Management

· Fund Management Service
·Investment Subject

– Singapore Bio company aiming to go public on KRX and NASDOQ

– Bio company on preclinical stage to first clinical stage

– New Treatment (Car_T Treatment, Anti-Cancer, Bispecific antibody, Exosome), Bio healthcare platform

· Size of Investment and Duration

– 10 billion ~ 30 billion

– Year of Maturity: 5 years

· Investment Procedure


Singapore local Bio company visit


Document and IR


LP Road-show


Due Diligence


Term sheet and contract


Investment

“ THE LEADING SOUTHEAST ASIAN CROSS-BOARDER COMPANY OF KOREA ”

footer